Cargando…
Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders
After marketing authorisation, the development of a medicinal product often continues with studies investigating new therapeutic indications. Positive results can potentially lead to changes to the terms of the marketing authorisation, such as an extension of therapeutic indication(s). These studies...
Autores principales: | Mulder, Jorn, Verjans, Robin, Verbaanderd, Ciska, Pean, Elias, Weemers, Just, Leufkens, Hubert G. M., Pignatti, Francesco, de Boer, Anthonius, Voest, Emile E., Stoyanova-Beninska, Violeta V., Pasmooij, Anna M. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695872/ https://www.ncbi.nlm.nih.gov/pubmed/34957158 http://dx.doi.org/10.3389/fmed.2021.790782 |
Ejemplares similares
-
A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach
por: Mulder, Jorn, et al.
Publicado: (2022) -
Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023) -
Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021) -
Dose‐Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis
por: Schuller, Yvonne, et al.
Publicado: (2018) -
Editorial: The use of real world data for regulatory purposes in the rare diseases setting
por: Giannuzzi, Viviana, et al.
Publicado: (2022)